In the past decade, there has been a growing interest in the application of continuous processing in the pharmaceutical industry with 100s millions of investments and several products delivered to the market using this technology.

Continuous processing demonstrates several value propositions for the Pharmaceutical industry. Amongst them, we can name, access to better chemistry, product quality enhancement, reduction of CoGs but mostly speed to market where phase 3 to launch is drastically accelerated.

Sanofi R&D is building capacities to perform future GMP clinical batches using this technology. The first investment was completed last year, and we are in the process of expansion. It is a really changing time for science at Sanofi.

Sanofi is investing in modular concepts with a high capability of production of API and the ability of infinite reconfiguration. We are not only a thinking machine; to enhance our ability to always produce the best quality drugs for our patients, we are also implementing a digital twin system, tracking and controlling the quality of our product at any moment of time.

We are ready to meet the challenges of tomorrow and produce the new APIs to help patients.


Flavien Susanne, Head of Chemical Development Engineering at Sanofi;
Sean Bermingham, Head of Formulated Products at Siemens PSE

Watch below

More Information


116 mins